Table 1.

Baseline demographic and clinical characteristics of the ketamine-treated sample and the case–control sample.

	Ketamine-Treated Sample (n = 16)		Case-Control Sample (n = 16)
Race, n (%)
White	13	(81.3%)	13	(81.3%)
Black	3	(18.8%)	2	(12.5%)
Unknown		--	1	(6.3%)
Gender, n (%)
Female	8	(50%)	8	(50%)
Male	7	(43.8%)	7	(43.8%)
Transgender (female-to-male)	1	(6.3%)	1	(6.3%)
Age, mean (SD)	34.06	(16.06)	35.56	(16.46)
Taking psychotropic medication at time of index SA, n (%)	15	(93.8%)	14	(87.5%)
Number of psychotropic medications, mean (SD)	2.67	(1.59)	2.64	(1.39)
Principal diagnoses, n (%) ¥
Unipolar
Major Depressive Disorder	5	(31.3%)	2	(12.5%)
Major Depressive Disorder w/Psychotic Features	2	(12.5%)	0	(0%)
Depressive Disorder NOS	2	(12.5%)	7	(43.8%)
Bipolar
Bipolar I Disorder	4	(25%)	2	(12.5%)
Bipolar I Disorder w/Psychotic Features	1	(6.3%)	1	(6.3%)
Bipolar II Disorder	2	(12.5%)	2	(12.5%)
Other Bipolar and Related	0	(0%)	2	(12.5%)
Comorbid alcohol- or substance-use disorder, n (%)	5	(31.3%)	2	(12.5%)

Note: No variables in the table above differed as a function of group (ketamine-treated vs. case–control patients) according to unpaired t-tests (for continuous variables) or Chi-squared tests (for categorical variables) (p’s > 0.19). ^¥ Established by the Mini International Neuropsychiatric Interview for ketamine patients and the Electronic Medical Record review for case–control patients; this led to an increased prevalence of non-specific diagnoses (Depressive Disorder NOS; Other Bipolar and Related) in case–control patients who were not given a structured interview to clarify diagnosis. Groups were matched on the presence of unipolar vs. bipolar forms of depression at baseline.